tiprankstipranks
Advertisement
Advertisement

BMRN Stock Latest News

BioMarin-Backed ENERGY 2 Trial Targets High-Value Niche in Ultra-Rare Infant Disease
Company AnnouncementsBioMarin-Backed ENERGY 2 Trial Targets High-Value Niche in Ultra-Rare Infant Disease
21d ago
BMRN
Buy Rating on BioMarin: Strong Early Voxzogo Data, Real‑World Durability, and Underpenetrated Achondroplasia Opportunity Drive Upside
PremiumRatings
Buy Rating on BioMarin: Strong Early Voxzogo Data, Real‑World Durability, and Underpenetrated Achondroplasia Opportunity Drive Upside
23d ago
BMRN
Wells Fargo says buy BioMarin shares amid Phase 2 trial discontinuation weakness
PremiumThe Fly
Wells Fargo says buy BioMarin shares amid Phase 2 trial discontinuation weakness
23d ago
BMRN
BioMarin Halts VOXZOGO Dosing in Select Phase 2 Trials
PremiumCompany Announcements
BioMarin Halts VOXZOGO Dosing in Select Phase 2 Trials
23d ago
8K
BMRN
BioMarin discontinues enrollment in some Phase 2 Voxzogo trials
PremiumThe Fly
BioMarin discontinues enrollment in some Phase 2 Voxzogo trials
23d ago
BMRN
BioMarin’s Voxzogo shows impact in pediatric achondroplasia
PremiumThe FlyBioMarin’s Voxzogo shows impact in pediatric achondroplasia
27d ago
BMRN
BioMarin: Strategic Amicus Acquisition Supports Buy Rating Despite Voxzogo Assumption Reset
Premium
Ratings
BioMarin: Strategic Amicus Acquisition Supports Buy Rating Despite Voxzogo Assumption Reset
28d ago
BMRN
BioMarin price target lowered to $85 from $97 at BofA
Premium
The Fly
BioMarin price target lowered to $85 from $97 at BofA
28d ago
BMRN
FOLD
BioMarin price target raised to $105 from $80 at Barclays
PremiumThe Fly
BioMarin price target raised to $105 from $80 at Barclays
1M ago
BMRN
BioMarin price target raised to $105 from $80 at Barclays
PremiumThe Fly
BioMarin price target raised to $105 from $80 at Barclays
1M ago
BMRN
BioMarin announces U.S FDA approved sBLA for Palynziq
PremiumThe Fly
BioMarin announces U.S FDA approved sBLA for Palynziq
1M ago
BMRN
BioMarin price target raised to $104 from $98 at Canaccord
PremiumThe Fly
BioMarin price target raised to $104 from $98 at Canaccord
1M ago
BMRN
FOLD
BioMarin price target raised to $94 from $90 at Bernstein
PremiumThe FlyBioMarin price target raised to $94 from $90 at Bernstein
1M ago
BMRN
BioMarin price target lowered to $86 from $106 at Guggenheim
Premium
The Fly
BioMarin price target lowered to $86 from $106 at Guggenheim
1M ago
BMRN
FOLD
BioMarin price target lowered to $55 from $60 at H.C. Wainwright
Premium
The Fly
BioMarin price target lowered to $55 from $60 at H.C. Wainwright
1M ago
BMRN
BioMarin Earnings Call Highlights Growth, Pipeline, Deals
PremiumCompany Announcements
BioMarin Earnings Call Highlights Growth, Pipeline, Deals
1M ago
BMRN
BioMarin price target lowered to $95 from $98 at Oppenheimer
PremiumThe Fly
BioMarin price target lowered to $95 from $98 at Oppenheimer
1M ago
BMRN
FOLD
BioMarin price target lowered to $97 from $102 at BofA
PremiumThe Fly
BioMarin price target lowered to $97 from $102 at BofA
1M ago
BMRN
BioMarin: Strong Q4 Beat, Solid Multi‑Year Outlook, and Strategic Amicus Acquisition Support Buy Rating
PremiumRatings
BioMarin: Strong Q4 Beat, Solid Multi‑Year Outlook, and Strategic Amicus Acquisition Support Buy Rating
1M ago
BMRN
BioMarin: Competitive Voxzogo Headwinds Offset by Pipeline Upside and Undervalued Long‑Term Growth Potential
PremiumRatingsBioMarin: Competitive Voxzogo Headwinds Offset by Pipeline Upside and Undervalued Long‑Term Growth Potential
1M ago
BMRN
Balanced Risk-Reward Amid Evolving Growth Profile and Rising Competition at BioMarin
Premium
Ratings
Balanced Risk-Reward Amid Evolving Growth Profile and Rising Competition at BioMarin
1M ago
BMRN
BioMarin reports Q4 non-GAAP EPS 46c, consensus 56c
Premium
The Fly
BioMarin reports Q4 non-GAAP EPS 46c, consensus 56c
1M ago
BMRN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >